Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 1
2002 1
2003 1
2004 1
2005 1
2006 1
2008 2
2010 2
2012 3
2013 1
2016 1
2017 1
2018 3
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ, Lin RS, Royer-Joo S, Liang X, Salphati L, Morrissey KM, Mahrus S, McCall B, Pirzkall A, Munn DH, Janik JE, Khleif SN. Nayak-Kapoor A, et al. Among authors: mahrus s. J Immunother Cancer. 2018 Jun 20;6(1):61. doi: 10.1186/s40425-018-0351-9. J Immunother Cancer. 2018. PMID: 29921320 Free PMC article. Clinical Trial.
Global kinetic analysis of proteolysis via quantitative targeted proteomics.
Agard NJ, Mahrus S, Trinidad JC, Lynn A, Burlingame AL, Wells JA. Agard NJ, et al. Among authors: mahrus s. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):1913-8. doi: 10.1073/pnas.1117158109. Epub 2012 Jan 23. Proc Natl Acad Sci U S A. 2012. PMID: 22308409 Free PMC article.
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, Ochoa de Olza M, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL. Jung KH, et al. Among authors: mahrus s. Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15. Clin Cancer Res. 2019. PMID: 30770348 Free PMC article. Clinical Trial.
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC. Italiano A, et al. Among authors: mahrus s. Ann Oncol. 2018 May 1;29(5):1304-1311. doi: 10.1093/annonc/mdy076. Ann Oncol. 2018. PMID: 29788155 Free article. Clinical Trial.
Tags for labeling protein N-termini with subtiligase for proteomics.
Yoshihara HA, Mahrus S, Wells JA. Yoshihara HA, et al. Among authors: mahrus s. Bioorg Med Chem Lett. 2008 Nov 15;18(22):6000-3. doi: 10.1016/j.bmcl.2008.08.044. Epub 2008 Aug 19. Bioorg Med Chem Lett. 2008. PMID: 18762420 Free PMC article.
The DegraBase: a database of proteolysis in healthy and apoptotic human cells.
Crawford ED, Seaman JE, Agard N, Hsu GW, Julien O, Mahrus S, Nguyen H, Shimbo K, Yoshihara HA, Zhuang M, Chalkley RJ, Wells JA. Crawford ED, et al. Among authors: mahrus s. Mol Cell Proteomics. 2013 Mar;12(3):813-24. doi: 10.1074/mcp.O112.024372. Epub 2012 Dec 20. Mol Cell Proteomics. 2013. PMID: 23264352 Free PMC article.
21 results